Recruiting
Phase 1
Phase 2

DRP-104 & Durvalumab

Sponsor:

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Code:

NCT06027086

Conditions

Fibrolamellar Hepatocellular Carcinoma

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Durvalumab

DRP-104

Study Details

Brief summary:

The purpose of this study is to determine whether the combination of subcutaneous DRP-104 in combination with intravenous Durvalumab is safe and yields a clinically compelling antitumor activity measured as based on objective response rate (ORR, assessed by RECIST 1.1). Secondary objectives include progression-free survival (PFS) and overall survival (OS).

Conditions

Fibrolamellar Hepatocellular Carcinoma

Study ID

NCT06027086

Start date

Feb 12, 2024

Status verified date

Feb, 2026

Completion date

Sep 1, 2033

Anticipated

Primary completion date

Sep 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Must have histologically confirmed FLC (Fibrolamellar Carcinoma) that is metastatic or unresectable.
  • Presence of DNAJB1-PRKACA fusion transcript, assessed by RNA-sequencing, DNA-sequencing, or in situ hybridization in the archival tissue.
  • Must have demonstrated radiographic progression on prior or current immunotherapy.
  • Age ≥ 12 years.
  • Patients < 18 years old must have a body weight ≥ 40 kg.
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
  • Patients must have adequate organ and marrow function defined by study-specified laboratory tests.
  • Patients must have adequate kidney and liver function defined by study-specified laboratory tests.
  • Must have measurable disease per RECIST 1.1
  • Willingness to provide tissue and blood samples for mandatory translational research.
  • Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test.
  • For both Women and Men, must use acceptable form of birth control while on study.
  • Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

  • Must have had chemotherapy or other systemic therapy or radiotherapy, as follows:

  • Patients who have had chemotherapy, biological cancer therapy, or radiation 21 days prior to the first dose of study drug.
  • Patients who have had surgery within 28 days of dosing of investigational agent, excluding minor procedures.
  • Patients who have received other approved or investigational agents or device within 21 days of the first dose of study drug.
  • Patients who have not recovered from acute adverse events to grade ≤1 or baseline due to agents administered, with exception of grade 2 fatigue, rash, and endocrinopathy successfully managed hormone replacement therapy, or alopecia or stable neuropathy, unless approved by the investigational new drug (IND) Sponsor.
  • Patients with corrected QT interval (QTc) prolongation > 470 ms according to Fridericia formula.
  • Patients receiving potent inducers of Cytochrome P450 3A (CYP 3A4/5) (including apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin and St. John's Wort) that cannot be discontinued at least 14 days prior to Cycle 1 Day 1.
  • Known sensitivity to or history of allergic reactions attributed to compounds of similar chemical or biologic composition of DRP-104 or durvalumab.
  • Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity.
  • Has a pulse oximetry of <92% on room air or is on supplemental home oxygen.
  • Active or untreated brain metastases or leptomeningeal metastases.
  • Uncontrolled intercurrent active medical and/or psychiatric illness/social psychosocial problems that that would limit compliance with study requirements.
  • Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant or breastfeeding.
  • Has a known history of Human Immunodeficiency Virus (HIV)/AIDS.
  • Has active hepatitis B. Patients with chronic or acute hepatitis B virus (HBV) infection .
  • Have had evidence of active or acute diverticulitis, intra-abdominal abscess, or GI obstruction which are known risk factors for bowel perforation should be evaluated for the potential need for additional treatment before coming on study.
  • Patient is unwilling or unable to follow the study schedule for any reason.
  • Patient is at the time of signing informed consent a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).
  • Evidence of clinical ascites.
  • Participants a with history of prior unacceptable and/or life-threatening toxicities attributed to anti-programmed death-receptor 1 (PD1) or anti-PD-L1 (anti-programmed death-receptor 1) therapy.
  • Has active autoimmune disease that has required systemic treatment in the past 2 years.
  • Prior allogeneic stem cell transplantation or organ transplantation.
  • Has a diagnosis of immunodeficiency.
  • Systemic corticosteroids at immunosuppressive doses.
  • Patients who have had either of the following procedures or medications within 4 weeks prior to initiation of study treatment:
  • Any live, attenuated vaccine
  • Allergen hypo sensitization therapy in the last 2 weeks

Study Design

Enrollment

27 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Durvalumab and DRP-104

Interventions

Durvalumab

Patients will receive treatment on Day 1 of each cycle. Durvalumab (1500 mg) will be administered IV on Day 1 of each cycle every 28 days.

DRP-104

Patients will receive treatment twice a week of each cycle. DRP-104 (145 mg,125mg, 105mg, 85mg or 65mg) will be administered subcutaneous injection twice a week of each 28 day cycle.

After the first cycle of treatment the study drug may be shipped to the patient's home for future cycles of administration if patients or caregiver can demonstrate at least two observed independent injections of DRP-104 prior to home administration.

Primary outcome measure

  • Number of participants experiencing drug-related adverse events (AEs) requiring treatment discontinuation [ Time Frame: 4 years ]
  • Objective response rate (ORR) using immune Response Evaluation Criteria for Solid Tumors (RECIST 1.1) [ Time Frame: 4 years ]

Central Contacts and Locations

Central contacts

Colleen Apostal, RN

410-614-3644GIClinicalTrials@jhmi.edu

Locations

Johns Hopkins SKCCC

Recruiting

Baltimore, Maryland, United States, 21231

Contacts

Colleen Apostal, RN

410-614-3644GIClinicalTrials@jhmi.edu

Principal Investigator:

Marina Baretti, MD

More Information

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Last update posted

Feb 12, 2026

Last verified

Feb, 2026

Keywords

  • Fibrolamellar Carcinoma (FLC)
  • Durvalumab
  • DRP-104 (glutamine antagonist)
  • Immunotherapy
  • Anti PD-L1
  • PD-L1
  • Carcinoma
  • Glutamine antagonist

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-27. This information was provided to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins on 2026-02-12. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.